Cytoplasmic domain of the β‐amyloid protein precursor of Alzheimer's disease: Function, regulation of proteolysis, and implications for drug development | Zendy

Kerr Megan L. | Zendy; Small David H. | Zendy

Premium

Cytoplasmic domain of the β‐amyloid protein precursor of Alzheimer's disease: Function, regulation of proteolysis, and implications for drug development

Author(s) -

Kerr Megan L.,

Small David H.

Publication year - 2005

Publication title -

journal of neuroscience research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.72

H-Index - 160

eISSN - 1097-4547

pISSN - 0360-4012

DOI - 10.1002/jnr.20408

Subject(s) - proteolysis , cytoplasm , drug development , amyloid precursor protein , amyloid (mycology) , function (biology) , disease , drug , microbiology and biotechnology , neuroscience , alzheimer's disease , chemistry , biology , biochemistry , pharmacology , medicine , pathology , enzyme , inorganic chemistry

The β‐amyloid protein precursor (APP) has been extensively studied for its role in amyloid production and the pathogenesis of Alzheimer's disease (AD). However, little is known about the normal function of APP and its biological interactions. In this Mini‐Review, the role of the cytoplasmic domain of APP in APP trafficking and proteolysis is described. These studies suggest that proteins that bind to the cytoplasmic domain may be important targets for drug development in AD. © 2005 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research